21Shares XRP ETF (TOXR): Entry into a Material Definitive Agreement

21Shares XRP ETF (TOXR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Benchmark Licensing Agreement On August 20, 2026, 21Shares US LLC (the “Sponsor”) entered into a licensing agreement (the “Benchmark Licensing Agreement”) with FTSE International Limited (“FTSE” or the “Benchmark Provider”). E

Event · Contract
Role
customer
Counterparty
FTSE International Limited
Scope
access, view and use the FTSE XRP Index
Duration
one-year initial term

Facts are quoted from the filing text and checked against it.

Original reporting
Published Aug 26, 2026, 8:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$TOXR
Neutral
medium confidence
Mentioned
$TOXR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TOXRNeutralLow
01

Why it matters

The ETF's pricing methodology changes, which may affect NAV and investor sentiment.

02

Market read

A filing that updates the ETF's benchmark, relevant for traders holding or considering the ETF.

03

What to watch

Potential fee changes associated with the new licensing agreement.

Relevance 6/10Novelty 7/10Timing: post‑market filing on Aug 26 2026

Background

SEC Form 8‑K filing details a material definitive agreement for the 21Shares XRP ETF.

Company-level read

Ticker impact

$TOXRNeutralMedium confidence
Context

21Shares filed an 8‑K reporting a new Benchmark Licensing Agreement to use the FTSE XRP Index for pricing the 21Shares XRP ETF.

Expected impact

Modest impact on ETF price as market adjusts to new benchmark methodology.

Evidence & confidence

The change is operational and does not involve large capital flows, but it updates the ETF's valuation framework.

Market effects

May influence other crypto‑linked ETFs that consider benchmark changes.

Limited to US ETF market; no broader regional effect.

Minimal global impact beyond crypto‑ETF niche.

Counterpoint

The benchmark switch could be seen as a risk if the new index underperforms the previous reference rate.

Key entities

  • 21Shares US LLC

    Sponsor of the 21Shares XRP ETF.

  • FTSE International Limited

    Provider of the FTSE XRP Index used as the new pricing benchmark.

Related articles

$CLPTMed

ClearPoint Neuro Raises ATM Offering Capacity to $150 Million With Stifel

ClearPoint Neuro (CLPT) increased its ATM offering capacity to $150M from $50M via an amended agreement with Stifel. The company can sell shares through Stifel, with $27.5M available under the current prospectus. Additional sales require a new supplement. CLPT controls timing, price, and size of sales, paying up to 3% in commissions. The amendment was signed and effective on Nov 18, 2026.

$ASTSMed

AST SpaceMobile Sinks 8% as New Offering Filing Revives Dilution Fears

AST SpaceMobile (ASTS) fell 8% after filing for a new securities sale, raising dilution concerns. The company's share count rose from 200M to 300M between late 2024 and Q3 2026. AT&T (T) and Vodafone (VOD), which have stakes in AST, are also affected. AST's free cash flow was negative $1.8B over the last four quarters, with analysts expecting negative free cash flow through 2028.